{
    "clinical_study": {
        "@rank": "3257", 
        "arm_group": [
            {
                "arm_group_label": "VAC VeraFlo with Dakins Instillation", 
                "arm_group_type": "Active Comparator", 
                "description": "VAC VeraFlo with Dakins .125% instillation will be initially applied in the OR after surgical debridement. Dressing will be changed on day 4 and and removed on day 7. Wound assessments will continue at weeks 2, 3, and 4."
            }, 
            {
                "arm_group_label": "VAC Ulta Therapy", 
                "arm_group_type": "Active Comparator", 
                "description": "VAC ULTA Therapy will be initially applied in the OR after surgical debridement. Dressing will be changed on day 4 and and removed on day 7. Wound assessments will continue at weeks 2, 3, and 4."
            }
        ], 
        "brief_summary": {
            "textblock": "This study would like to determine if using negative pressure wound therapy with an\n      instillation of .125% Dakins is more effective than using negative pressure wound therapy\n      alone on biofilm removal, disruption and elimination in chronically infected lower extremity\n      wounds."
        }, 
        "brief_title": "V.A.C. VeraFlo\u2122 Instillation Therapy vs V.A.C. Ulta\u2122 Therapy on Biofilm in Chronically Infected Wounds", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Lower Extremity Wound Infected", 
            "Venous Stasis Ulcers"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Postphlebitic Syndrome", 
                "Postthrombotic Syndrome", 
                "Varicose Ulcer", 
                "Ulcer", 
                "Wound Infection"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The patient is of 18 years or older.\n\n          -  Males and females - provided they are not pregnant and if of reproductive age are\n             using contraception.\n\n          -  Patient with ulcers that:\n\n               1. Have an ulcer area of at least 4 cm2 confirmed via counting squares on an wound\n                  tracing\n\n               2. Have been present for at least 4 weeks\n\n               3. Are confirmed to have a colony forming unit per gram of wound tissue greater\n                  than or equal to 10 to the 5th cfu\n\n               4. Are full thicknesses through to dermal or subcutaneous tissue but not extending\n                  to muscle or bone.\n\n               5. The patient has an ABI of greater or equal to 0.8 and lower than 1.3 or has a\n                  suitable Peripheral Vascular Resistance (PVR) and Doppler assessment which\n                  confirms venous disease & therefore treatment with Profore is deemed acceptable\n                  by the clinician.\n\n               6. The patient has one or more clinical signs of infection (edema, malodor,\n                  local/periwound erythema, spontaneous pain between dressing changes, increased\n                  exudate, discoloration of granulation tissue, increased temperature at wound,\n                  non progression of wound, purulent exudate and friable granulation tissue)\n\n               7. The patient is able to understand the evaluation and is willing to consent to\n                  the evaluation.\n\n               8. Patients with a suitable wound on a different limb to any other wounds\n                  previously eligible.\n\n        Exclusion Criteria:\n\n          1. Patients undergoing chemotherapy\n\n          2. Patients being treated with immunosuppressive drugs or corticosteroids\n\n          3. Patients with an autoimmune disease\n\n          4. Patients who have participated in an experimental drug or device study within the\n             last 15 days\n\n          5. Patients that have been entered in this evaluation previously as an evaluable\n             patient."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02009501", 
            "org_study_id": "VAC/09/05/ULTA"
        }, 
        "intervention": [
            {
                "arm_group_label": "VAC VeraFlo with Dakins Instillation", 
                "description": "VAC VeraFlo  with Dakins instillation will be placed in the operating room after surgical debridement. Biopsies will be obtained prior to surgical debridement, after surgical debridement, on day 4, and on day 7.", 
                "intervention_name": "VAC VeraFlo with Dakins Instillation", 
                "intervention_type": "Device", 
                "other_name": [
                    "NPWTi", 
                    "VAC Instill"
                ]
            }, 
            {
                "arm_group_label": "VAC Ulta Therapy", 
                "description": "VAC ULTA will be placed in the operating room after surgical debridement. Biopsies will be obtained prior to surgical debridement, after surgical debridement, on day 4, and on day 7.", 
                "intervention_name": "VAC Ulta Therapy", 
                "intervention_type": "Device", 
                "other_name": [
                    "VAC", 
                    "NPWT"
                ]
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Infected wounds", 
            "NPWTi", 
            "VAC Instill", 
            "Biofilm"
        ], 
        "lastchanged_date": "December 8, 2013", 
        "location": {
            "contact": {
                "email": "cgendics@chpnet.org", 
                "last_name": "Cynthia A Gendics, RN", 
                "phone": "212-523-2979"
            }, 
            "contact_backup": {
                "email": "jlantis@chpnet.org", 
                "last_name": "John C Lantis, MD", 
                "phone": "212-523-4797"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10025"
                }, 
                "name": "St. Luke's-Roosevelt Hospital Center"
            }, 
            "investigator": {
                "last_name": "John C Lantis, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective, Open, Comparative, Randomized Single-center Study to Evaluate the Effect of V.A.C. VeraFlo\u2122 Therapy With .125% Dakins vs V.A.C. Ulta\u2122 Therapy on Biofilm Removal/Disruption/Elimination in Chronically Infected Wounds", 
        "overall_contact": {
            "email": "cgendics@chpnet.org", 
            "last_name": "Cynthia A Gendics, RN", 
            "phone": "212-523-2979"
        }, 
        "overall_contact_backup": {
            "email": "jlantis@chpnet.org", 
            "last_name": "John C Lantis, MD", 
            "phone": "212-523-4797"
        }, 
        "overall_official": {
            "affiliation": "St. Luke's-Roosevelt Hospital Center", 
            "last_name": "John C Lantis, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Biopsies for bacteria colony-forming units will be obtained at pre surgical debridement (baseline), post surgical debridement, day 4 and day 7.", 
            "measure": "Evaluate the change in bacteria colony-forming units using when NPWT and NPWTi on venous leg ulcers", 
            "safety_issue": "No", 
            "time_frame": "Baseline through day 7"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02009501"
        }, 
        "responsible_party": {
            "investigator_affiliation": "St. Luke's-Roosevelt Hospital Center", 
            "investigator_full_name": "John Lantis", 
            "investigator_title": "Chief, Vascular-Endovascular Surgery", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "St. Luke's-Roosevelt Hospital Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Kinetic Concepts, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "John Lantis", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}